ID
49
Beskrivning
Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation. Inclusion criteria: - Documented (12-lead ECG) history of symptomatic atrial fibrillation occurring between 48 hours and 6 months before screening - Require the procedure of cardioversion (electric shock to correct abnormal rhythm) - In the investigator's opinion, is likely to maintain sinus rhythm after cardioversion. - Be anticoagulated according to the recommendations of the Study Group on Atrial Fibrillation of the European Society of Cardiology guidelines. Exclusion criteria: - Previously unsuccessful electrical cardioversions - Failed to respond to any Class III antiarrhythmic drugs - Qualifying arrhythmia due to acute reversible illness, acute myocardial infarction, and/or cardiac or thoracic surgery within one month prior to randomization
Nyckelord
Versioner (2)
- 2011-11-11 2011-11-11 -
- 2014-03-21 2014-03-21 - Martin Dugas
Uppladdad den
11 november 2011
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0 Legacy
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Criteria NCT00035451 AF
Similar models
Eligibility
- StudyEvent: Eligibility
439401001 (SNOMED CT 2010_0731)
49436004 (SNOMED CT 2010_0731)
10003658 (MedDRA 13.1)
427.31 (ICD-9-CM Version 2011)
I48.0 (ICD-10-CM Version 2010)
E10081 (CTCAE Version 4.03)
46825001 (SNOMED CT 2010_0731)
10014084 (MedDRA 13.1)
250980009 (SNOMED CT 2010_0731)
10007661 (MedDRA 13.1)
LP97905-1 (LOINC Version 232)
260678004 (SNOMED CT 2010_0731)
67507000 (SNOMED CT 2010_0731)
44808001 (SNOMED CT 2010_0731)
10003119 (MedDRA 13.1)
I49.9 (ICD-10-CM Version 2010)
427.9 (ICD-9-CM Version 2011)